China This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Merck’s $2.13B deal with SciBrunch for KRAS G12D inhibitor SPR2015, Abogen’s $7.78B partnership with Novartis for an mRNA T-cell engager, and 3SBio’s ¥1.75B GLP-1 deal with MindRank. Other updates feature AstraZeneca’s $2B investment in Summit, Hengrui’s $2.6B GLP-1/GIP deal…
APAC The global AI-in-clinical-trials market is forecast to grow at a 22.6 percent CAGR through 2030, reaching roughly USD 6.5 billion, as sponsors push CROs to demonstrate concrete efficiency gains rather than incremental process tweaks. That growth is already visible on the ground in APAC: AI has moved well beyond the…
China China has rapidly become the world’s leading country for clinical trial volume, alongside the stratospheric growth of its local biotech industry, which now accounts for almost a third of the global drug development pipeline. The high speed and low cost of Chinese trials are unmatched globally. However, in a volatile…
China Chinese biotechs are now outpacing multinationals at getting drugs into pivotal trials — but MNCs still win the race to final approval. In this piece from the September 2026 edition of DIA Global Forum, Li Wang of Lilly’s China Drug Development & Medical Affairs Center digs into fresh 2023–2025 timeline…
China Excalipoint is betting that the next chapter of T-cell engagers will be written in solid tumours, where the modality is beginning to challenge the boundaries of cancer immunotherapy. Co-Founder, Chairman and CEO/CSO Dr Lei Fang explains how two decades of T-cell research underpin a differentiated pipeline, a China-first global development…
China CirCode Biomed is emerging at the forefront of a small but fast-evolving field seeking to turn circular RNA into a new class of medicines. From its roots in pioneering academic research, the Chinese biotech has moved circRNA into the clinic while building a diversified pipeline across ischaemic disease, in vivo…
China Chinese pharmaceutical companies are increasingly seeking drug approval in the EU, US, and Australia, beyond the NMPA. Daphne Smyth of Veristat has witnessed this shift firsthand, advising sponsors on data gaps, supplementary studies, and the regulatory quirks that stand in the way of a drug developed in China gaining marketing…
Global Five conferences, anxiety spreading across five continents, one unmistakable pattern: the global pharmaceutical industry is transforming at a dizzying pace. From Philadelphia to Geneva, from Istanbul to Chicago and London, the Shawview Consulting team picked up the same recurring threads in every panel and hallway conversation: AI and real-world data…
APAC For two decades the case for running a clinical trial in Asia was essentially arithmetic: the same study, for less money. That argument has not gone away, but it is no longer the one APAC’s own CRO leaders make. Asia Pacific is now the only region in the world where…
China Our goal is to generate rigorous clinical data demonstrating that these therapies can deliver meaningful and lasting benefits for patients For decades, neurological diseases such as Parkinson’s disease, spinal cord injury, MSA and ALS have remained among the most difficult conditions to treat, with available therapies largely focused on managing…
China China has built one of the world’s most advanced digital health ecosystems — large, fast-moving, and integrated across hospitals, internet platforms, insurers, pharmaceutical companies, and regulators. AI is now embedded across the entire value chain: drug discovery, clinical trial management, medical imaging, patient triage, and hospital workflows. Insilico Medicine is…
China As the global clinical development landscape becomes more fragmented and competitive, biotechs increasingly need partners that can help them navigate regulatory complexity, identify the right trial locations, and generate meaningful data quickly. In this context, Harvest Integrated Research Organization has been expanding its international footprint while positioning itself as a…
See our Cookie Privacy Policy Here
